drugset / Trial / NCT03846310
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and clinical activity of etrumadenant (AB928) in combination with carboplatin and pemetrexed, with or without an anti-PD-1 antibody (pembrolizumab or zimberelimab), in participants with non-squamous Non-Small Cell Lung Cancer (NSCLC).
Timeline
- Start
- 2019-04-01
- Primary completion
- 2024-11-18
- Completion
- 2024-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etrumadenant | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Zimberelimab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |